Cargando…

Usefulness of Global Longitudinal Strain-Guided Management in Preventing Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor-Induced Myocardial Damage

Background: Trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is a specific first-line treatment for patients with HER2-positive cancers. Cardiac dysfunction is among the most problematic adverse events associated with trastuzumab. Although regular echocardiog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Kenta, Tamura, Yudai, Taniguchi, Hirohisa, Furukawa, Asuka, Iwasawa, Jin, Yada, Hirotaka, Kawamura, Akio, Tamura, Yuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2022
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638510/ https://www.ncbi.nlm.nih.gov/pubmed/36408358 http://dx.doi.org/10.1253/circrep.CR-22-0094

Ejemplares similares

Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy
por: Tamura, Yudai, et al.
Publicado: (2022)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Case Report: BMPR2-Targeted MinION Sequencing as a Tool for Genetic Analysis in Patients With Pulmonary Arterial Hypertension
por: Takashima, Tomoya, et al.
Publicado: (2021)

Pulmonary hypertension associated with neurofibromatosis type 2
por: Taniguchi, Hirohisa, et al.
Publicado: (2021)

How COVID-19 Affected the Introduction of Telemedicine and Patient Reported Outcomes Among Patients With Pulmonary Hypertension　― A Report From a Referral Center in Japan ―
por: Tamura, Yuichi, et al.
Publicado: (2020)

Case report: Pathological differences in pulmonary arterial hypertension in long-term responders to calcium channel blockers
por: Tamura, Yuichi, et al.
Publicado: (2023)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Usefulness of Longitudinal Strain to Assess Cancer Therapy-Related Cardiac Dysfunction and Immune Checkpoint Inhibitor-Induced Myocarditis
por: Tamura, Yudai, et al.
Publicado: (2023)

Current clinical understanding and effectiveness of portopulmonary hypertension treatment
por: Tamura, Yuichi, et al.
Publicado: (2023)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Predictors of hypoxemia in type-B acute aortic syndrome: a retrospective study
por: Tamura, Yudai, et al.
Publicado: (2021)

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
por: Takagi, Shinji, et al.
Publicado: (2014)

Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
por: Yamamoto, Noboru, et al.
Publicado: (2009)

Epidermal Growth Factor Prolongs Survival Time of Tumor‐bearing Mice
por: Amagase, Harunobu, et al.
Publicado: (1990)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

Impaired peripheral insulin sensitivity in non‐obese Japanese patients with type 2 diabetes mellitus and fatty liver
por: Furukawa, Yasuhiko, et al.
Publicado: (2017)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
por: Shin, Daniel Sanghoon, et al.
Publicado: (2016)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
por: Wakui, Hiroshi, et al.
Publicado: (2014)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Platypnoea–orthodeoxia syndrome induced by short-term weight loss: a case series
por: Tamura, Yudai, et al.
Publicado: (2020)

Endocarditis Caused by Zoonotic Pathogens and Antiphospholipid Syndrome Are Possible Differential Diagnoses: Authors' Reply
por: Tamura, Yudai, et al.
Publicado: (2021)

How do the 2022 European Society of Cardiology/European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis
por: Atsukawa, Masanori, et al.
Publicado: (2023)

Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report
por: Gibo, Takahiko, et al.
Publicado: (2019)

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
por: Schrohl, Anne-Sofie, et al.
Publicado: (2011)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022)

Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
por: Mudgal, Shikha, et al.
Publicado: (2023)

Tranexamic Acid Controlled Chronic Disseminated Intravascular Coagulation Associated with Aortic Dissection and Patent False Lumen for Three Years
por: Gatate, Yodo, et al.
Publicado: (2017)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model
por: Nakayama, Akiko, et al.
Publicado: (2013)

STA-A3 Bypass Using Radial Artery Graft for Progressive Cerebral Infarction of Bilateral ACA Region after STA-MCA Bypass Surgery for Moyamoya Disease
por: Hirano, Yudai, et al.
Publicado: (2022)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Mitotic phosphorylation of Pex14p regulates peroxisomal import machinery
por: Yamashita, Koichiro, et al.
Publicado: (2020)

Infected Abdominal Aortic Aneurysm with Helicobacter cinaedi
por: Nishida, Kazuhiro, et al.
Publicado: (2016)

SATISFY‐JP, a phase II multicenter open‐label study on Satralizumab, an anti‐IL‐6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune‐responsive‐phenotype: Study protocol
por: Tamura, Yuichi, et al.
Publicado: (2023)

Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma
por: Sugano, Teppei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6nm93gbe4dr3vn6899ptpguk7h